Orofacial Strength and Voice Quality as Outcome of Levodopa Challenge Test in Parkinson Disease

Orofacial Strength and Voice Quality as Outcome of Levodopa Challenge Test in Parkinson Disease:

Objective

To assess the usefulness of orofacial strength and voice quality as assessment of response to levodopa challenge test (LCT) used in the diagnosis of early idiopathic Parkinson disease (IPD).

Study Design

Controlled Prospective Study.

Methods

From January 2014 to April 2019, patients with early IPD and healthy individuals were recruited and evaluated for clinical findings (Hoehn and Yahr scale; Unified Parkinson's Disease Rating Scale); Voice Handicap Index (VHI); grade of dysphonia, roughness, breathiness, asthenia, and strain and instability (GRBASI); maximal phonation time; phonation quotient; acoustic parameters; and orofacial muscle strength Oral Performance Instrument (IOPI; IOPI Medical, Woodinville, WA, USA) t) at baseline and 45 minutes after the levodopa intake (LCT).

Results

A total of 32 IPD patients and 20 healthy individuals completed the study. Healthy individuals exhibited better VHI, grade of dysphonia, breathiness, asthenia, strain, instability, and acoustic measurements (noise‐related, tremor, F0 short‐ and mid‐term and intensity short‐term parameters) than healthy subjects. The mean values of muscle strength of lips, cheeks, fundamental frequency (F0), highest F0, and shimmer significantly improved from pre‐ to post‐LCT in IPD patients. Healthy individuals did not exhibit significant changes of orofacial strength and voice quality assessment from pre‐ to post‐LCT. Significant associations were found between clinical, orofacial strength, and some aerodynamic and acoustic measurements.

Conclusion

Orofacial strength and acoustic voice quality measurements may be used as objective outcomes of the LCT responsiveness in patients with early IPD.

Level of Evidence

3A. Laryngoscope, 2020